idarubicin (idamycin) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Idarubicin is an antineoplastic in the anthracycline class.Idarubicin hydrochloride is a DNA-intercalating analog of daunorubicin which has an inhibitory effect on nucleic acid synthesis and interacts with the enzyme topoisomerase II. The absence of a methoxy group at position 4 of the anthracycline structure gives the compound a high lipophilicity which results in an increased rate of cellular uptake compared with other anthracyclines.Idarubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. Idarubicin in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults.   NCATS

Chemistry

  • SMILES: CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O
  • InChIKey: XDXDZDZNSLXDNA-TZNDIEGXSA-N
  • Mol. Mass: 497.5
  • ALogP: 1.02
  • ChEMBL Molecules:
    idarubicin  
    idarubicin hydrochloride  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$5.8845 - $9.5010

Australia

$23.1892
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranoside | 4-demethoxydaunomycin | 4-demethoxydaunorubicin | 5,12-naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7s-cis)- | demethoxydaunorubicin | idamycin | idamycin pfs | idarubcin | idarubicin | idarubicina | idarubicine | idarubicin hcl | idarubicin hydrochloride | idarubicin hydrochloride pfs | idarubicinum | imi-30 | zavedos

Organizations (217)

Research & Development (209)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (48)

Approved Indications (1)


 

Leukemia, Myeloid, Acute (approved 1990)

Experimental Indications - Clinical Trial Phases 1-4 (48)


 

Anemia, Refractory (Phase 3)

Bone Marrow Cells (Phase 2)

Breast Neoplasms (Phase 2)

Burkitt Lymphoma (Phase 4)

Carcinoma, Hepatocellular (Phase 2/Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Drugs, Investigational (Phase 2)

Geriatrics (Phase 3)

Graft vs Host Disease (Phase 2)

Hematologic Neoplasms (Phase 1)

Hematopoietic Stem Cell Transplantation (Phase 2/Phase 3)

Induction Chemotherapy (Phase 3)

Leukemia (Phase 4)

Leukemia, Biphenotypic, Acute (Phase 2)

Leukemia, Eosinophilic, Acute (Phase 2)

Leukemia, Erythroblastic, Acute (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 4)

Leukemia, Lymphoid (Phase 2)

Leukemia, Megakaryoblastic, Acute (Phase 1)

Leukemia, Monocytic, Acute (Phase 3)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 4)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 4)

Leukemia, Myeloid, Chronic-Phase (Phase 2)

Leukemia, Myelomonocytic, Acute (Phase 3)

Leukemia, Myelomonocytic, Chronic (Phase 3)

Leukemia, Promyelocytic, Acute (Phase 4)

Leukemia, T-Cell (Phase 2/Phase 3)

Liver Cirrhosis (Phase 1)

Liver Neoplasms (Phase 2)

Lymphoma (Phase 4)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 4)

Lymphoma, Large-Cell, Immunoblastic (Phase 2/Phase 3)

Lymphoma, Non-Hodgkin (Phase 4)

Multiple Myeloma (Phase 3)

Mutation (Phase 1)

Myelodysplastic Syndromes (Phase 4)

Myeloproliferative Disorders (Phase 3)

Neoplasms by Histologic Type (Phase 1)

Neutropenia (Phase 3)

Plasmacytoma (Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 4)

Sarcoma (Phase 3)

Sarcoma, Myeloid (Phase 2)

Translocation, Genetic (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 226
  • # of Trial Organizations: 209

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue